Healthcare · Knowledge & Insight
Automate Executive Reporting in Pharmaceuticals with AI
We design, build, and run AI-native executive reporting for pharma commercial teams, medical affairs, pharmacovigilance leaders, and market access teams. This page describes the engagement: scope, pricing, timeline, controls, and the KPIs we commit to.
Early access: we work with a small first cohort. Engagements are scoped, priced, and shipped end-to-end by our team — not referred to third parties.
In one sentence
AI-native executive reporting for pharmaceuticals is a phased engagement (Discovery 2.5 weeks → Build 7 weeks → Run continuous) that ships a production workflow on top of CRM and medical information systems, moves reporting cycle time by −81% against the pharmaceuticals baseline, and is operated under knowledge & insight governance from day one.
Key facts
- Industry
- Pharmaceuticals
- Use case
- Executive Reporting
- Intent cluster
- Knowledge & Insight
- Primary KPI
- reporting cycle time, decision clarity, follow-through, and executive alignment
- Top benchmark
- Cost per executive briefing: $1 800 → $340 (−81%)
- Systems integrated
- CRM, medical information systems, safety databases
- Buyer
- pharma commercial teams, medical affairs, pharmacovigilance leaders, and market access teams
- Risk lens
- medical accuracy, adverse event handling, promotional compliance, privacy, and audit trails
- Engagement timeline
- Discovery 2.5 weeks → Build 7 weeks → Run continuous
- Team size
- 2 senior delivery (1 architect + 1 implementer)
- Discovery price
- $6k · 2-week sprint
- Build price
- $22k–$30k · 7-10 weeks
Primary outcome
give leadership clearer operating visibility with less manual reporting
What we ship
board reporting assistant, KPI narratives, risk register, and operating review pack
KPIs we report on
reporting cycle time, decision clarity, follow-through, and executive alignment
Why Pharmaceuticals teams hire us for this
Most pharmaceuticals teams have already run an AI pilot. Most pilots stalled at "interesting demo, no production traffic, no measurable lift". AI-native delivery on executive reporting starts where those pilots stalled: from week one, the workflow runs on real pharmaceuticals data, real reviewers, and a baseline you can defend in a CFO review.
Foundational RAG research (Lewis et al., 2020) and follow-up work on long-context limitations (Liu et al., 2023) inform how we architect retrieval for pharmaceuticals: hybrid search + reranking + grounded citations, not raw long-context dumping.
Industry context: Mid-market and enterprise operators face the same fundamental tradeoff: AI must compress operational cycle time while remaining auditable and integrable with existing systems of record.
Benchmarks we hit
Reference benchmarks from production deployments of executive reporting in pharmaceuticals-comparable contexts. Sources noted per row. Your actuals are measured against the baseline captured in Discovery.
| Metric | Industry baseline | AI-native typical | Delta |
|---|---|---|---|
Cost per executive briefing Analyst time reallocated from assembly to validation and narrative | $1 800 | $340 | −81% |
Source citation completeness Every claim grounded in approved source with replayable retrieval bundle | 38% | 100% | +62 pts |
Time-to-insight (analyst query → answer) Source-grounded retrieval + structured output; analyst validates rather than searches | 3.2 hours | 11 minutes | −94% |
Benchmarks are reference values from comparable engagements and authoritative sector benchmarks. Your engagement's baseline is captured during Discovery and actuals are reported weekly during Run against that baseline.
How we operate the workflow
Run cadence on executive reporting is calibrated to pharmaceuticals reality, not consultant fantasy. We do not promise daily prompt updates — we promise weekly. We do not promise instant model swaps — we promise quarterly evaluations against new candidates. The promise is operational reliability, not heroic effort, because heroic effort does not survive the third month.
What we build inside the workflow
The Build engagement ships three production layers. The intake layer classifies every request, record, or signal into a measurable taxonomy. The context layer retrieves approved source material — policy, customer history, prior cases, operational notes. The action layer summarizes metrics, explains movement, drafts narratives, and highlights decisions needed. Each layer is wrapped with review queues, confidence scoring, audit logs, and dashboards before any production traffic.
Reference architecture
4-layer AI-native workflow for knowledge & insight
Source intake → AI orchestration → Action → Human review & quality.See the full architecture diagram for Knowledge & Insight →
AI-native vs traditional approach
How a scoped AI-native engagement compares to the traditional alternatives for executive reporting in pharmaceuticals.
| Dimension | Traditional (in-house build or BPO) | AI-native engagement (us) |
|---|---|---|
| Time to production | 6-12 months | 6-10 weeks (thin slice) |
| Pricing model | FTE hourly retainer or fixed staffing | Phased fixed-price (Discovery → Build → opt Run) |
| Audit / governance | Manual logs, periodic review | Versioned prompts, audit logs, reviewer queues, attestations |
| Operator throughput lift | 1.0× (baseline) | +62 pts |
| Cost per unit | Industry baseline | AI-native engagements deliver thin-slice production in 6-8 weeks with measurable baseline-vs-actuals reporting. |
| Exit path | Multi-quarter notice + knowledge loss | Month-to-month Run, full handover plan in Build SoW |
Traditional process automation projects cost $80-200k+ with 6-12 month payback; AI-native engagements deliver thin-slice production in 6-8 weeks with measurable baseline-vs-actuals reporting.
Engagement scope & pricing
We run this as a fixed-scope engagement with a clear commercial envelope, not an open-ended retainer.
Insight engagement
Three phases, billed separately. You commit one phase at a time.
Phase 1 · Discovery
$6k
2-week sprint
Phase 2 · Build
$22k–$30k
7-10 weeks
Phase 3 · Run
$3k–$5k / mo
optional, hourly bank also available
~$34k–$60k typical year 1 (60% take the run option for ~6 months)
Source curation, retrieval architecture, evaluation harness, and decision dashboards.
Discovery is the only commitment to start. After Discovery, we scope Build with a fixed price. Run is opt-in, month-to-month, no lock-in.
The 4-phase delivery model
Phase 1 · Weeks 1–2
Discovery
We map the workflow, the systems, the decisions, and the baseline metrics. Output: a scoped statement of work.
Phase 2 · Weeks 2–4
Design
We design the operating model: data access, retrieval, prompts, review queues, controls, and the KPI dashboard.
Phase 3 · Weeks 4–8
Build
We ship a production thin slice on real data, with versioned prompts, evaluation harness, and human review.
Phase 4 · Weeks 8+
Run
We run the workflow with you weekly, expand into adjacent work, and report against baseline.
Interactive ROI calculator
Estimate your AI-native ROI for executive reporting
Reference inputs below are typical for pharmaceuticals teams in the knowledge insight cluster. Adjust them to match your situation.
Projected
Current monthly cost
$26,400
AI-native monthly cost
$6,684
Annual savings
$236,592
75% cost reduction · ~1,672 operator-hours freed / month
Governance and risk controls
medical accuracy, adverse event handling, promotional compliance, privacy, and audit trails. Those concerns are addressed by architecture, not by policy documents. We ship a control map alongside the workflow — what data sources are approved, what model versions are deployed, what reviewer queues exist, what escalation paths trigger, what attestation cadence we run. The map is on the same dashboard as the workflow metrics, not in a shared drive nobody reads.
How we report ROI
For pharmaceuticals CFOs evaluating executive reporting engagements, the cleanest ROI framing is unit economics: cost per case before vs after, throughput per FTE before vs after, error rate before vs after. We instrument all three from the Discovery baseline and report against them weekly. No abstract "productivity gain" claims; concrete dollars and minutes.
Common pitfall & mitigation
The failure mode we see most often on AI-native executive reporting engagements in pharmaceuticals contexts.
Long-context dumping vs hybrid retrieval
Engineering shoves 200k tokens of corpus into context, accuracy plateaus
Hybrid retrieval (BM25 + embeddings + reranker) + targeted chunks; eval harness benchmarks both approaches
Build internally or work with us
The strongest pattern we see in pharmaceuticals is blended: we design and launch the first production workflow, your internal team owns data access, security review, and stakeholder alignment. Over 6-12 months, your team takes over Run while we move to the next workflow. The exit plan is part of the Statement of Work.
What to ask us before signing
- Ask for a workflow map that shows intake, retrieval, generation, review, escalation, system updates, and measurement.
- Ask for an evaluation plan using real examples from pharmaceuticals, not only generic test prompts.
- Ask how we will move reporting cycle time, decision clarity, follow-through, and executive alignment within the first 30 to 60 days.
- Ask which parts of the process remain human-owned and why.
- Ask for our exit plan: what stays with you if the engagement ends.
Recommended first project
The best first project for AI-native executive reporting in pharmaceuticals is a contained workflow with enough volume to matter and enough structure to evaluate. Avoid the most politically sensitive process first. Avoid a workflow with no measurable baseline. Choose a process where we can ship a production-grade thin slice, prove adoption, and then extend the same architecture to neighboring work.
A practical target is a 30-day build followed by a 60-day operating period. In the first 30 days, we map the work, connect the minimum data sources, build the assistant, and create the review process. In the next 60 days, the system handles real volume, the team measures outcomes, and we improve the workflow weekly. By day 90, leadership knows whether to expand into adjacent work.
Frequently asked questions
How do you automate executive reporting in pharmaceuticals with AI?+
We map the existing executive reporting workflow inside pharmaceuticals, identify the high-volume, high-structure tasks, and build an AI agent that handles those tasks while routing low-confidence cases to a human reviewer. The build connects to your CRM, medical information systems, safety databases, runs against a labelled test set, and ships behind a reviewer queue before it sees production traffic. We then operate it, measure reporting cycle time, decision clarity, follow-through, and executive alignment, and improve it weekly.
What does it cost to automate executive reporting for a pharmaceuticals company?+
Three phases, billed separately. Discovery sprint: $6k (2-week sprint). Build engagement: $22k–$30k (7-10 weeks). Run retainer: $3k–$5k / mo (optional, hourly bank also available). ~$34k–$60k typical year 1 (60% take the run option for ~6 months). Source curation, retrieval architecture, evaluation harness, and decision dashboards.
What is the best AI agent for executive reporting in pharmaceuticals?+
There is no single "best" off-the-shelf agent for executive reporting in pharmaceuticals — the right architecture depends on your CRM setup, your data, and your risk profile. We typically combine a frontier LLM (Claude, GPT-4-class, or Gemini) with a retrieval layer over your approved sources, tool-use for CRM and medical information systems integrations, and a reviewer queue. We benchmark candidate models against a labelled test set during Discovery and pick the one with the best accuracy/cost ratio for your workflow.
How long does it take to deploy AI executive reporting for pharmaceuticals?+
A thin-slice deployment in 2-week sprint after Discovery, with real pharmaceuticals data and real reviewers. The full Build phase runs 7-10 weeks. By day 90, reporting cycle time, decision clarity, follow-through, and executive alignment is instrumented, the team has a baseline, and leadership has the data needed to decide on expansion into adjacent pharmaceuticals workflows.
What do we own, and what do you own?+
We own the workflow design, the prompts, the retrieval architecture, the evaluation harness, and weekly improvement. Your pharma commercial teams, medical affairs, pharmacovigilance leaders, and market access teams team owns data access, policy, exception approval, and final commercial decisions. At the end of the engagement, every prompt, eval, and config is handed over — no lock-in.
How do you guarantee AI answer quality for executive reporting in pharmaceuticals?+
We curate sources, run an evaluation harness against a labelled test set, and require citations for every generated answer. We report on reporting cycle time, decision clarity, follow-through, and executive alignment and on test-set accuracy weekly.
Sources we reference
The following sources inform the architecture, governance, and benchmarks we apply on pharmaceuticals engagements. Cited here so you can verify and dig deeper.
- FDA Artificial Intelligence
- AI Risk Management Framework (AI RMF 1.0) — NIST
- OECD AI Principles — OECD
- Lost in the Middle: How Language Models Use Long Contexts — Liu et al., Stanford
- Knowledge Worker Productivity in the AI Era — Microsoft Work Trend Index
- Google Search Central: helpful, reliable, people-first content
- Google Search Central: URL structure best practices
Start the engagement
Book a discovery call for Pharmaceuticals
Tell us about your workflow, the systems involved, and the KPI you want to move. We'll send a scoped statement of work within 5 business days.